Physician profile
Elsayed A Hussein
NPI 1326130535
$23,275.64
in general payments reported to CMS, 2019-2025
56 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,302 · 2020: $2,293 · 2021: $2,585 · 2022: $5,483 · 2023: $5,033 · 2024: $2,781 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,598 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,598.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,642.14 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $2,271.59 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,089.49 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $1,816.52 | 2020-2024 | |
| Novo Nordisk INC | $1,746.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,490.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,376.84 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,304.76 | 2019-2025 | Xifaxan, Cycloset |
| Lilly USA, LLC | $1,291.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $666.48 | 2022 | |
| Currax Pharmaceuticals LLC | $585.76 | 2019-2025 | Contrave, Onzetra Xsail |
| Merck Sharp & Dohme LLC | $518.85 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $474.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $460.61 | 2022-2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $366.26 | 2024-2025 | Voquezna |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsayed Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.